Global Idiopathic Pulmonary Fibrosis (IPF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035
- Published Date : November 20, 2025
- Updated On : April 9, 2026
- Pages : 156
Global Idiopathic Pulmonary Fibrosis (IPF) Market Outlook
Thelansis’s “Global Idiopathic Pulmonary Fibrosis (IPF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Pulmonary Fibrosis treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Idiopathic Pulmonary Fibrosis (IPF) Overview
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and ultimately fatal fibrosing interstitial lung disease of unknown aetiology, characterised by aberrant epithelial injury responses, fibroblast activation, and excessive extracellular matrix deposition — producing the pathological hallmark of usual interstitial pneumonia (UIP) — resulting in irreversible destruction of lung architecture and progressive respiratory failure. Genetic susceptibility variants, particularly MUC5B promoter polymorphisms, alongside ageing, cigarette smoking, gastro-oesophageal reflux, and occupational dust exposures are recognised risk determinants. Patients — predominantly older males — present insidiously with progressive exertional dyspnoea, dry cough, and bibasal inspiratory velcro-like crackles, with clubbing present in a significant proportion. Diagnosis integrates high-resolution CT demonstrating characteristic UIP pattern — subpleural, basal-predominant honeycombing with or without traction bronchiectasis — alongside pulmonary function testing revealing restrictive physiology and reduced DLCO; surgical lung biopsy is reserved for diagnostically uncertain cases. Antifibrotic therapies — nintedanib and pirfenidone — slow FVC decline and disease progression but do not reverse established fibrosis. Lung transplantation remains the only potentially life-extending intervention in eligible patients. Pulmonary rehabilitation, supplemental oxygen, and proactive management of comorbidities — including pulmonary hypertension and acute exacerbations — are essential. Prognosis remains poor with median survival of two to five years; early palliative integration, advance care planning, and compassionate patient-centred support are indispensable throughout the disease trajectory.
Market Definition:
- North America (United States, Canada)
- Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
- Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
- Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt, Nigeria, South Africa, Morocco)
- South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Global Idiopathic Pulmonary Fibrosis (IPF) Market Outlook
Thelansis’s “Global Idiopathic Pulmonary Fibrosis (IPF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Pulmonary Fibrosis treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).
Idiopathic Pulmonary Fibrosis (IPF) Overview
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and ultimately fatal fibrosing interstitial lung disease of unknown aetiology, characterised by aberrant epithelial injury responses, fibroblast activation, and excessive extracellular matrix deposition — producing the pathological hallmark of usual interstitial pneumonia (UIP) — resulting in irreversible destruction of lung architecture and progressive respiratory failure. Genetic susceptibility variants, particularly MUC5B promoter polymorphisms, alongside ageing, cigarette smoking, gastro-oesophageal reflux, and occupational dust exposures are recognised risk determinants. Patients — predominantly older males — present insidiously with progressive exertional dyspnoea, dry cough, and bibasal inspiratory velcro-like crackles, with clubbing present in a significant proportion. Diagnosis integrates high-resolution CT demonstrating characteristic UIP pattern — subpleural, basal-predominant honeycombing with or without traction bronchiectasis — alongside pulmonary function testing revealing restrictive physiology and reduced DLCO; surgical lung biopsy is reserved for diagnostically uncertain cases. Antifibrotic therapies — nintedanib and pirfenidone — slow FVC decline and disease progression but do not reverse established fibrosis. Lung transplantation remains the only potentially life-extending intervention in eligible patients. Pulmonary rehabilitation, supplemental oxygen, and proactive management of comorbidities — including pulmonary hypertension and acute exacerbations — are essential. Prognosis remains poor with median survival of two to five years; early palliative integration, advance care planning, and compassionate patient-centred support are indispensable throughout the disease trajectory.
Market Definition:
- North America (United States, Canada)
- Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
- Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
- Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt, Nigeria, South Africa, Morocco)
- South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)